#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Philip Low Email
Chief Science Officer . Endocyte
How to contact Philip Low
Join and see Philip's contact info for free!Current Roles
Employees:
18Revenue:
$1.8MAbout
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma.Endocyte Address
Purdue Research ParkWest Lafayette, IN
United States